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1. Introduction
Solubility is one of the most important molecular 
properties of drugs. It plays a key role in determin-
ing their absorption potential and has fundamen-
tal impact on the bioavailability therefore. Solubili-
ty data refers to the given physical form of a solid 
compound thereby it is significantly affected by 
polymorphism. Polymorphism – the ability of a 
substance to exist as two or more crystalline forms 
that have different arrangements and/or conforma-
tions of the molecules in the crystal lattice – is com-
mon among the pharmaceutical solids [1]. More 
than one third of drugs show polymorphism and a 
further one third is capable of forming hydrates 
and solvates [2]. This subject has gained intensive 
attention in both original and generic drug re-
search since in case of several drugs polymor-
phism caused serious safety problems [3]. The 
most known examples (from chloramphenicol pal-
mitate, through carbamazepine, oxytetracycline, 
enalapril, etc. up to ritonavir) have been extensive-
ly reported in the literature [4-8]. These cases in-
duced severe regulatory considerations [9] result-
ing that polymorph screening and the investiga-
tion of physico-chemical properties and stability of 
different polymorphic forms has become inevitable 
during the process of drug development [10, 11]. 
Polymorphs have different lattice energy so they 
differ in those physical and chemical properties 
which associated with the internal free energy of 
the solid, such as: density, refractivity, conductivi-
ty, hygroscopicity (packing properties); melting 
temperature, vapor pressure, solubility (thermody-
namic properties); dissolution rate, stability (kinet-
ic properties); and several others (surface, mechan-
ical, spectroscopic properties) [2]. From absorption 
and bioavailability point of view the solubility and 
the dissolution rate are the most relevant proper-
ties of a pharmaceutical compound, however from 
formulation and safety aspects stability is also es-
sential. A general rule is that a polymorph having 
the lower lattice free energy is the more stable form 
and it has the lower solubility while that having 
higher energy is less stable but tends to dissolve 
faster and has higher solubility [1]. Based on litera-
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ture solubility data Pudipeddi and Serajuddin [12] 
published a survey that the ratio of metastable/
stable polymorph solubility is typically less than 
2, though occasionally higher ratios can be ob-
served as reported for sulindac (7x difference be-
tween From I and II) [13] and for premafloxacin 
(23x) [14], etc. Similar trend was found for anhy-
drate/hydrate solubility ratio (~2) with many ex-
ceptions, while the amorphous/crystalline forms 
solubility differs with factor ~10, generally. Solu-
bility difference of polymorphs will have effect on 
the bioavailability/bioequivalence (BA/BE) of a 
drug product if the solubility is the rate limiting 
factor upon absorption (for BCS II and IV drugs). 
Solubility characterized by the equilibrium sol-
ubility data is the concentration of the compound 
in a saturated solution when solid and solute are 
at equilibrium. This parameter can be measured 
by several methods however the “gold standard” 
is still the saturation shake-flask technique (SSF). 
Recently Avdeef et al. published a consensus-
based “white paper” commentary which summa-
rized the recommendations for solubility mea-
surement including SSF and other methods to im-
prove the data quality [15]. The paper pointed out 
to the difficulties in the measurement of poly-
morphs due to the possible polymorph transi-
tions upon equilibration and the importance of 
the analysis of both solution and solid phases. 
Well established methods for solid phase analysis 
(X-ray powder diffraction XRPD, differential 
scanning calorimetry DSC, FT-IR and Raman 
spectroscopy, etc.) should be used for character-
ization of the solid at the beginning and also at 
the end of the solubility experiment. Adhering 
and applying all these recommendations of the 
“white paper” one can measure only the thermo-
dynamic solubility of that crystalline form which 
is in dynamic equilibrium with its solution form, 
at the temperature of the experiment. However, 
during the dissolution process polymorphs can 
show different kinetics, resulting in substantially 
various supersaturation solutions even so if later 
they convert to another form. The incubation time 
in the standard protocol of SSF is 24 h (6 h agita-
tion and 18 h sedimentation) [16]. Since solvent 
induced changes in solid form structure might oc-
cur much faster or slower than this timeframe the 
in situ monitoring of the dissolution-time profile 
may provide more information about the behav-
ior of polymorphs and may enable the optimiza-
tion of incubation time. Moreover in situ monitor-
ing with fiber optic UV probes under certain con-
ditions (low amount of excess solid, long analysis 
time, etc) enables the determination of dissolution 
kinetics and also equilibrium solubility from a 
single experiment. 
The goals of the present study were: (1) investi-
gation of equilibrium solubility of different poly-
morphs of venlafaxine hydrochloride (VENL) as 
model compound, in wide pH range by SSF 
method coupled with solid phase analysis; (2) 
real time monitoring of the dissolution profile us-
ing in situ UV fiber optic; (3) to compare the equi-
librium solubility results obtained by SSF and 
µDISS methods and (4) to reveal the advantages 
and limits of the latter technique for solubility 
measurement.
2. Material and methods
2.1. Materials
The structure of model compound is presented in 
Figure 1. Venlafaxine hydrochloride (313.86 g/mol) 
was purchased from Sigma-Aldrich Co. LLC. (St. 
Louis, MO, USA). From the commercially avail-
able polymorph the other polymorphic form was 
prepared in house based on patent (US6924393B2) 
and verified by XRPD. Distilled water of Ph. Eur. 
grade was used. All other reagents were of analyt-
ical grade. 
A Britton-Robinson (BR) buffer stock solution (a 
mixture of acetic acid, phosphoric acid and boric 
acid, each at 0.04 M) was prepared, and the re-
quired amount of 0.2 M NaOH or 1M NaOH was 
added to give the pH specified for the solubility 
experiments. BR buffer solutions were used in pH 
range 7.5-11, while at pH 11 and above NaOH was 
applied.
Figure 1 Structure of venlafaxine hydrochloride
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2.2. Determination of the thermodynamic solubility by 
saturation shake-flask method (SSF)
2.2.1. Preparation of saturated solution
The equilibrium solubility of VENL in the exam-
ined pH region was determined by the SSF meth-
od [16, 17]. The sample was added in excess to the 
aqueous buffer solutions to produce a suspension. 
The amount of solid added was accurately mea-
sured: 10-300 mg/4 mL. At controlled temperature 
of 25.0 ± 0.1 °C the solution containing solid excess 
of the sample was vigorously stirred for a period 
of 6 h (agitation time), what followed a further 18 h 
of sedimentation period (stirrer turned off).
 2.2.2. Concentration determination of the saturated 
solution
2.2.2.1. Off-line: sampling, dilution and concentration 
measurement with UV spectrophotometer
The concentration of the saturated solution was 
measured by UV spectroscopy using JASCO V 550 
UV/VIS spectrophotometer. Three aliquots were 
carefully withdrawn from the liquid, using a fine 
glass pipette, and were diluted with the solvent if 
necessary. Three replicate solubility measure-
ments were carried out at each of the tested condi-
tions. 
The specific absorbance (A1%1cm, the absor-
bance of 1 g/100 mL solution over a 1 cm optical 
pathlength at a given wavelength) of VENL was 
determined separately at pH 8.0 using 12 points 
of two parallel dilution series, from the linear 
regression equation (Lambert-Beer law) where 
the regression coefficient (r) was higher than 
0.9998. The specific absorbance data obtained is 
38.4 at λmax 273.5 nm. This value was used for 
concentration calculation at all pHs since the 
UV spectrum of VENL is not pH-dependent 
due to the distance between the protonation site 
(aliphatic N atom) and the chromophore in the 
structure. 
2.2.2.2. In situ: with fiber optic UV probe
µDISS ProfilerTM (Pion Inc. Billerica MA, US, Figure 2) 
has been applied as UV fiber optic instrumenta-
tion. The equilibrium concentration was concomi-
tantly determined in situ in the equilibrated solu-
bility suspension (without dilution) immersing the 
UV dip probe. Calibration was performed with 
the same (2-5-10-20 mm) tip adjusted to the fiber 
optic UV dip probe which was used in the given 
solubility experiment. Solubility values obtained 
from the same experiments analysed with both 
the off-line and the in situ UV method were com-
pared (see section 3.3.).
2.3. In situ real time monitoring of dissolution, 
supersaturation, precipitation and the equilibrium 
solubility
The drug solution concentration versus time (0-24 h) 
was investigated with the µDISS ProfilerTM. The in-
strument measures the real time concentration 
with fiber optic UV dip probe inserted in 6 tem-
perature controlled 20 mL vessels, stirred with 
magnetic stirrer. Dissolution of VENL was regis-
tered in BR buffer pH ~ 11.5, in three parallel chan-
nels, where 10 mg sample was added to 4 mL dis-
solution media. Using the appropriate 2 mm  tip 
adjusted to the UV probe, the UV spectra were 
registered in the following timing protocol: per 
1 min in 0-2 h, per 10 min in 2-6 h and per 30 min 
in 6-24 h periods. The stirrer was turned off at 6 h. 
For the evaluation of the concentration previously 
determined calibration data and second derivative 
spectra were used. 
2.4. Methods for the analysis of the solid phase
2.4.1. XRPD
Small amount of the solid phase at the end of solu-
bility measurement was isolated and dried to a 
glass plate. X-ray powder diffraction patterns of 
these samples were recorded by means of a 
PANaly tical (Amelo, The Netherlands) X’pert 
ProMDP X-ray diffractometer using Cu-K”α radia-
tion (1.524 Ǻ) and a Ni filter. The applied voltage 
Figure 2 µDISS ProfilerTM
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was 40 kV, while the current was 30 mA. The sam-
ples were analysed between 4° and 42° 2θ.  
2.4.2. Raman spectroscopy
Raman spectra were collected using a Horiba Jobin-
Yvon LabRAM system coupled with an Olympus 97 
BX-40 optical microscope (Olympus Corporation, 
Tokyo, Japan). The sample was illuminated by a 
785-nm diode laser (TEC 510 type, Sacher Laser-
technik, Marburg, Germany) and an objective of ×10 
(laser spot size, approximately 4 µm) was used for 
optical imaging and spectrum acquisition. The laser 
beam is focused through the objective, and the 
backscattered radiation is collected with the same 
objective, a common configuration found in most 
confocal spectroscopic systems. The collected radia-
tion is directed through an edge filter that removes 
the Rayleigh photons and then through a confocal 
hole (500 µm) and the entrance slit (100 µm). Finally, 
a 950 groove/mm grating monochromator disperses 
the Raman photons before reaching the CCD detec-
tor. Each spectrum of the image was collected in the 
spectral range of 300 to 1600 cm−1.
2.4.3. Polarized light microscopy
Polarized light microscopic images were taken us-
ing Amplival (Carl Zeiss, Jena, Germany) type mi-
croscope coupled with Olympus C4040 Z type 
camera (Olympus, Japan).
2.5. Statistical analyses
Concentrations were expressed as means ± SD, 
and were compared using “two-sample” Student’s 
t test. Differences were considered statistically sig-
nificant when p < 0.05.
3. Results and Discussion
In this study we measured the equilibrium solu-
bility of different polymorphic forms of venlafax-
ine hydrochloride modelling the possible behav-
iour of a pharmaceutical solid. The pH-dependent 
equilibrium solubility (SpH) over a wide pH range 
was investigated by SSF method at 25 °C tempera-
ture. The solubility of the free base form was de-
picted by the intrinsic solubility (So) measured at 
high pH value. To identify the solid form that is 
present at the solubility equilibrium, the approach 
was completed with the solid phase analysis at the 
end of the solubility experiment. We also studied 
the dissolution kinetics and the extent of supersat-
uration and the incubation time needed to reach 
the equilibrium, using real time monitoring by 
µDISS ProfilerTM to reveal the differences between 
the stable and less stable/metastable forms. 
Venlafaxine is a 2nd generation, SNRI (serotonin-
norepinephrine reuptake inhibitor) antidepressant 
drug nowadays widely used in depression, in gen-
eralized anxiety disorder, post-traumatic stress dis-
order, etc. (US Patent, 2006, US7030164B2). VENL 
is used as racemate of its hydrochloride salt which 
is known to exist in two polymorphic forms, Form 
I and Form II. Though Form I is more stable (melt-
ing temperature: 210-212 °C, ΔH: 125.8 J/g) than 
Form II (melting temperature: 208-210 °C, 
ΔH: 130.3 J/g) the latter is preferred in the formula-
tion because it has larger particle size with better 
filtration and drying characteristics [18]. VENL is a 
monovalent base (pKa: 9.63), its solubility is pH-
dependent. Since the compound belongs to BCS I 
class, the solubility is not an absorption limiting 
factor from GI tract. Investigation of salt solubility 
in biorelevant medium was not the goal of this 
study. However VENL is a good model for study-
ing the pH-dependent solubility of polymorphs 
and for comparison the SSF and µDISS methods in 
the measurement of intrinsic solubility. 
Table I Equilibrium solubility of venlafaxine hydrochloride 
polymorphs in BR buffer measured by SSF method
VENL Form I VENL Form II
pH SpH ± SD
 (mg/mL)
n pH SpH ± SD
(mg/mL)
n
7.50 59.35 ± 8.23 9 7.54 54.32 ± 4.43 3
7.70 32.08 ± 2.60 9 7.60 45.67 ± 2.34 9
7.83 23.34 ± 0.45 3 7.67 38.35 ± 2.99 9
8.30 8.655 ± 0.267 9 7.78 26.79 ± 0.27 3
8.34 7.194 ± 0.043 3 8.20 8.175 ± 1.061 9
8.37 7.495 ± 0.601 3 8.40 7.689 ± 0.345 9
8.43 6.983 ± 0.103 3 8.52 5.506 ± 0.104 3
8.47 6.364 ± 0.071 3 8.58 4.985 ± 0.053 3
9.30 0.948 ± 0.031 9 8.64 4.587 ± 0.013 3
9.50 0.796 ± 0.094 9 8.70 3.809 ± 0.104 3
9.72 0.574 ± 0.011 3 9.45 0.831 ± 0.027 9
9.76 0.507 ± 0.004 3 9.76 0.567 ± 0.014 4
9.81 0.559 ± 0.062 3 9.96 0.544 ± 0.011 3
9.96 0.570 ± 0.013 3 10.06 0.495 ± 0.052 4
10.34 0.521 ± 0.186 3 10.26 0.523 ± 0.037 4
10.41 0.454 ± 0.011 3 10.41 0.498 ± 0.034 4
11.51 0.275 ± 0.004 4 11.62 0.296 ± 0.025 4
12.11 0.292 ± 0.007 4 12.01 0.285 ± 0.004 4
Concentration is expressed as free base equivalents. 
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3.1. Solubility-pH profile of venlafaxine polymorphs
The equilibrium solubility of VENL Form I and II 
were measured by the standard protocol of SSF 
method at 18 different points in pH range 7.5-12, at 
25 °C. The SpH ± SD results are expressed in mg/mL 
unit as average value of parallel measurements and 
are presented in Table I. The standard deviation was 
in the range of 1-13 %, average SD: 6 %. No signifi-
cant difference was found between the SpH values 
of polymorphs at the same pH in the whole exam-
ined region. This can be interpreted with the tran-
sition of polymorphs to a common product as sup-
ported by the solid phase analysis (see below 3.2). 
Figure 3 shows the solubility-pH profile of 
VENL Form I and Form II as plotted logS [M] val-
ues vs pH. As it can be seen in Figure 3 the curve is 
typical for a monoprotic base as described by the 
theoretical Henderson-Hasselbalch (HH) relation-
ship (logS = logS0 + log(10pKa-pH + 1) [17, 19]. 
The intrinsic solubility of VENL base (calculat-
ed as the average of values measured at pH ≥ 11.5) 
is logSo [M]: -2.93 ± 0.014 (n=4). This value was 
used to generate the HH curve of VENL (solid line 
on Figure 3). The experimental data points closely 
follow the theoretical HH curve. Below pH 10 the 
VENL free base starts to convert to cationic form 
and the solubility is increasing. Below pH 7 the 
solubility was not studied because the salt solubil-
ity is very high (> 500 mg/mL) and its saturated 
solution can be considered non-ideal solution.
3.2. Characterization of the solid phase isolated from 
solubility experiment
First the starting materials, Form I and Form II 
were identified by powder X-ray diffraction (see in 
Figure 4). Next the samples isolated and dried 
from the solubility suspension after incubation at 
different pHs were studied. Diffractograms shown 
representatively in increasing pH order in Figure 4 
demonstrate that the samples are not identical 
with the starting polymorphic forms in neither 
case. Results indicate that both polymorphs re-
Figure 3 Solubility-pH profile of VENL Form I and Form 
II (solid line represents the theoretical HH curve calculated 
from pKa: 9.63 and logSo: -2.93, points represent the 
experimental data)
Figure 4 XRPD patterns of VENL Form I and Form II and the solids isolated from solubility suspensions  
at different pH values
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crystallized to a common form. Product obtained 
at lower pHs (7.5-9) could not be identified using 
Cambridge Structural Database. Based on patent 
US20030114536A1 we identified the product as 
venlafaxine hydrochloride monohydrate. Patterns 
registered at higher pH (11-12) values were found 
identical with one of the free base VENL poly-
morphs, specified in the database as free base 
Form I. A peak (if any) appeared with various in-
tensity in the patterns of free base at 9 (2 Theta) is 
due to the presence of sodium acetate remained in 
some samples. XRPD finding was supported by 
Raman spectroscopy as well (Figure 5). The polar-
ized light microscopic images in Figure 6 (A and B 
panels) indicate that crystal shape of Form I and II 
is column but they substantially differ in their 
size. Panel C shows the shape of the free base 
form isolated at pH 12. 
All above results of solid phase analysis con-
firm and can interpret the equilibrium solubility 
data measured experimentally (Table I) in pH 
range 7.5-12. 
3.3. Comparison of concentration measurement with 
off-line UV method and in situ UV probe
µDISS ProfilerTM measures the concentration of the 
solute in situ in the saturated solution in the pres-
ence of solid. In order to prove that it has no im-
pact on the results (e.g. distorting the absorption 
measurement), in a part of SSF experiment at the 
end of incubation time the concentration of the 
saturated solution 
was measured by 





CO), and (2) in situ 
in the solubility 
vessel (without di-
lution) by UV 
probe (UV-µDISS). 
Solubility values 
shown in Table II 
are in good agree-
ment. Difference 
between the results 
Figure 5 Raman spectra of solid phase of VENL polymorphs isolated from solubility suspensions
Figure 6 Polar microscopic images of VENL samples (A: Form I, B: Form II, C: free base isolated at 
pH 12)
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varies in 0.2-15%, average is about 5%. It can be ob-
served that in 7/10 cases µDISS measures the low-
er value. 
3.4. Real time monitoring of dissolution by µDISS 
ProfilerTM
The real time dissolution profile was monitored 
by µDISS ProfilerTM. It was performed in BR buffer 
pH ~11-11.5 (exact pH was measured at the end of 
the experiments) in 0-24 h period, where in the 
first 6 h stirrer was turned on. The UV spectra 
were registered according to a protocol (see in sec-
tion 2.3.) in three parallel vessels and the concen-
tration was calculated using calibration. Figure 7 
shows that dissolution process of VENL can be 
followed well and the equilibrium solubility can 
Figure 7 Solubility-time profile of VENL Form I (upper panels) and Form II (lower panels) at pH ~ 11.5 in BR buffer 
monitored by µDISS approach
Table II Equilibrium solubility of venlafaxine hydrochloride 




SpH ± SD (mg/mL)
UV-JASCO UV-µDISS
Form I
7.50 59.35 ± 8.23 56.98 ± 6.89
7.70 32.08 ± 2.60 31.34 ± 2.40
7.83 23.34 ± 0.45 22.44 ± 0.31
9.30 0.948 ± 0.031 1.121 ± 0.038
9.50 0.796 ± 0.094 0.764 ± 0.080
Form II
7.54 54.32 ± 4.43 48.51 ± 6.32
7.60 45.67 ± 2.34 45.54 ± 1.25
7.67 38.35 ± 2.99 36.49 ± 0.45
7.78 26.79 ± 0.27 26.96 ± 0.40
9.45 0.831 ± 0.027 0.853 ± 0.030
Concentration is expressed as free base equivalents. 
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also be measured by this approach. In case of 
Form I (Figure 7 upper panels) the supersaturation 
is very similar in the three parallel experiments 
and solute reaches 3.5 times concentration relative 
to the equilibrium solubility. Precipitation starts at 
different time in the parallels (12-25-30 min, re-
spectively) and the samples are reaching the equi-
librium in rather short time (20-40 min). The con-
centration is not changing further when at 6 h 
stirrer is turned off up to 20 h. A small (~13%) in-
crease in concentration can be observed in 20-24 h 
period for one of the channels. It may be due to 
the adsorption of solid crystals to the UV probe 
without stirring of the suspension. The dissolu-
tion-time profile of Form II as starting material 
(Figure 7 lower panels) is very similar. It reaches a 
bit slower the same supersaturation as Form I but 
the precipitation and time needed to reach the 
equilibrium is the same. We can conclude from 
this profiling that VENL polymorphs are convert-
ing to the common free base form immediately af-
ter dissolution. Intrinsic solubility measured by 
µDISS ProfilerTM at 24 h is 0.290 ± 0.004 mg/mL 
(logSo [M]: -2.98) (n=4), it perfectly agrees with So 
obtained by SSF method. 
4. Conclusions
In this study we have demonstrated the impor-
tance of solid phase analysis in the solubility in-
vestigation of drug polymorphs giving reliable in-
formation about which form is present in solubili-
ty equilibrium. We presented an example for the 
possible behavior of pharmaceutical compounds. 
Venlafaxine hydrochloride Form I and Form II 
transformed to a common product in aqueous 
buffer solution in pH 7.5-12 region and thus the 
measured solubility values at a given pH were 
identical. Solid isolated from pH 10-12 was identi-
fied as the free base, while between pH 7-8 the iso-
lated common product was identified as VENL 
hydrochloride monohydrate based on XRPD re-
sults. Since VENL dissolves freely in acidic medi-
um not the solubility but the better manufactur-
ability can explain why the less stable Form II is 
preferably used in tablets.
We have also presented the good agreement of 
equilibrium solubility measured by SSF coupled 
with off-line analytics and in situ fiber optic con-
centration monitoring. µDISS ProfilerTM has the 
advantage to provide much more information 
about dissolution process, with this approach the 
dissolution kinetic, the supersaturation and the 
time needed to reach the equilibrium can be easily 
monitored. It is simpler and occasionally can be 
faster than traditional methods however there are 
limits of its application. Neither too high nor too 
low solubility can be measured with this instru-
ment, the optimal solubility window is about 
1-500 µg/mL. Since the new APIs in drug research 
are mainly poorly soluble compounds, for their 
solubility study µDISS Profiler seems to be advan-
tageous. 
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